Meet the Management

ImQuest Life Sciences will become a leader in the
development of exciting new drugs for unmet medical
needs throughout the world.

Robert W. Buckheit, Jr., Ph.D.

Co-Founder, Executive Vice President and CSO

Dr. Buckheit is a well-respected and internationally recognized virologist with over 20 years of experience in the research and development of therapies for human cancer and AIDS. His experiences include AIDS drug development, immunology, retrovirology, molecular biology and anti-viral and anti-cancer assay development. Educated and trained at Duke University and The University of North Carolina at Chapel Hill, Dr. Buckheit has focused on the development of anti-infective therapies to prevent the transmission and spread of infectious disease, including evaluation of efficacy and toxicity, range and mechanism of anti-infective action, anti-infective resistance, anti-infective combination therapy and animal model development.

Dr. Buckheit is well-versed in the use of both cell-based and molecular/biochemical assays as components of drug development algorithms and has participated in the development of dozens of compounds which have progressed to IND submission and human clinical testing. Dr. Buckheit has developed and managed anti-infective and anti-cancer drug development programs in the CRO sector for the bulk of his career, including the development of drugs for the therapy of HIV, hepatitis B & C, herpes simplex virus, respiratory and enteric viruses, bacterial and fungal pathogens and bio-defense related organisms.

At ImQuest, Dr. Buckheit has been awarded over $12 million in research grants from the National Institutes of Health, including Phase 1 and 2 Small Business Innovation Awards. Dr. Buckheit sits on the Editorial Boards of the journals Antiviral Research and Expert Opinion on Investigational Drugs and is an ad hoc reviewer for the Journal of Virology and Antimicrobial Agents and Chemotherapy as well as numerous other journals. Dr. Buckheit is also an active member of the International Society for Antiviral Research and is the Program Chair for the annual conference of the Society (ICAR). Dr. Buckheit has authored over 150 papers in the peer reviewed literature and regularly presents laboratory data at a variety of international scientific meetings.

Our Management

Robert W. Buckheit, Jr., Ph. D. - Co-Founder, Executive Vice President and CSO

Dan Williams, JD., LLM - Vice President of Tax and Chief Financial Officer

Daniel R. Caffoe - Co-Founder and Chairman of the Board